Genetic modifiers of upper limb function in Duchenne muscular dystrophy

Daniele Sabbatini1 · Aurora Fusto1 · Sara Vianello1 · Matteo Villa1 · Joanna Janik1 · Grazia D’Angelo2 · Eleonora Diella2 · Francesca Magri3 · Giacomo P. Comi3 · Chiara Panicucci4 · Claudio Bruno4 · Adele D’Amico5 · Enrico Bertini5 · Guja Astrea6 · Roberta Battini6 · Luisa Politano7 · Riccardo Masson8 · Giovanni Baranello8,9 · Stefano C. Previtali10 · Sonia Messina11 · Gianluca Vita11 · Angela Berardinelli12 · Tiziana Mongini13 · Antonella Pini14 · Marika Pane15,16 · Eugenio Mercuri15,16 · Eric P. Hoffman17,18 · Lauren Morgenroth18 · Heather Gordish-Dressman18 · Tina Duong18,19 · Craig M. McDonald20 · Luca Bello1 · Elena Pegoraro1

Received: 13 March 2022 / Revised: 5 April 2022 / Accepted: 7 April 2022 © The Author(s) 2022

Abstract
Genetic modifiers of Duchenne muscular dystrophy (DMD) are variants located in genes different from the disease-causing gene DMD, but associated with differences in disease onset, progression, or response to treatment. Modifiers described so far have been tested mainly for associations with ambulatory function, while their effect on upper limb function, which is especially relevant for quality of life and independence in non-ambulatory patients, is unknown. We tested genotypes at several known modifier loci (SPP1, LTBP4, CD40, ACTN3) for association with Performance Upper Limb version 1.2 score in an Italian multicenter cohort, and with Brooke scale score in the Cooperative International Neuromuscular Group Duchenne Natural History Study (CINRG-DNHS), using generalized estimating equation (GEE) models of longitudinally collected data, with age and glucocorticoid treatment as covariates. CD40 rs1883832, previously linked to earlier loss of ambulation, emerged as a modifier of upper limb function, negatively affecting shoulder and distal domains of PUL (\(p = 0.023\) and \(0.018\), respectively) in the Italian cohort, as well as of Brooke score (\(p = 0.018\)) in the CINRG-DNHS. These findings will be useful for the design and interpretation of clinical trials in DMD, especially for non-ambulatory populations.

Keywords Duchenne muscular dystrophy · Genetic modifiers · Upper limb function · SPP1–osteopontin · CD40

Introduction
Duchenne muscular dystrophy (DMD) is a severe and progressive muscle disease caused by complete dystrophin deficiency in muscle fibers. It is an X-linked recessive disease, with an incidence of around 1 in 3800–4200 male births and prevalence between 19.9 and 95.5 in 1,000,000. Usually, symptoms are present in early childhood with delayed motor milestones and difficulties in rising from the floor, typically with a Gowers’ maneuver, and in climbing stairs. Progressive muscle degeneration causes loss of independent ambulation (LoA) typically around the age of 13. Respiratory and cardiac involvement develop later, and are major causes of death [1].

Even if all DMD patients carry out-of-frame mutations that disrupt protein expression completely, still it is possible to observe a spectrum of phenotype severity within DMD [2–5]. This is primarily measured by age at LoA, because of its impact on daily life and the overall health of patients, and its correlation with overall survival and other disease milestones, such as the onset of respiratory insufficiency and the need for scoliosis surgery [6]. All of these disease milestones may vary by several years, e.g. loss of ambulation may ensue from before 10 years to after 15 years of age.
Phenotype variability in DMD may be caused by environmental (e.g. socioeconomic conditions, treatments) and genetic effects. The genetic effects can be further subdivided in “cis” and “trans” acting effects. The former ones are due to the DMD mutations themselves: in fact, in DMD patients, dystrophin may not always be completely absent from skeletal muscle fibers. Protein assays that are commonly used in the diagnostic setting have limited sensitivity, so that small amounts of protein may escape detection, while still exerting a measurable effect on the phenotype [6]. The “trans” acting factors are genetic modifiers, i.e. polymorphisms in genes different than DMD, which influence disease phenotype, affecting onset, progression, response to treatment, etc. Several loci have been shown to modify LoA in DMD: SPP1 rs28357094 [7], LTRBP4 rs10880, rs2303729 and rs1131620 [8], CD40 rs1883832 [9], ACTN3 rs1815739 [10], THBS1 rs2725797 and rs2624259 [11]. All these genes are involved in key features of DMD pathogenesis, such as inflammation, fibrosis, response to treatment, and muscle function [6, 12].

In the non-ambulatory stages of DMD, upper limb function obviously suffers a progressive decline, which strongly influences patient independence and quality of life. Therefore, dedicated outcome measures have been specifically developed, including the Brooke score [13] and the Performance Upper Limb (PUL) scale [14]. Here, we aimed to verify if genetic modifiers of LoA in DMD, both cis- and trans-acting, also affect the performance of the upper limbs measured with the PUL test. Moreover, all associations were tested for validation in an independent cohort (i.e. Cooperative International Neuromuscular Research Group Duchenne Natural History Study, CINRG-DNHS) in which patients had been tested using the Brooke scale. PUL was not available in the CINRG-DNHS, as the scale had not yet been designed at the time the DNHS protocol was finalized.

Methods

Patient selection

Retrospective data were collected from several Italian Centers (i.e. University of Padova, University of Milan, “Mondino” Institute in Pavia, IRCCS “Medea” in Bosisio Parini, “Besta” Neurological Institute in Milan, University of Turin, “Gaslini” Institute in Genova, IRCCS “Bellaria” in Bologna, IRCCS “Stella Maris” Pisa, “Bambin Gesù” Hospital in Rome, Catholic University of the Sacred Heart in Rome, University “Vanvitelli” in Naples, NEuroMuscular Omninceter NEMO in Messina). Inclusion criteria were: molecularly confirmed DMD diagnosis, at least one available PUL evaluation, and the availability of genomic DNA for SNPs genotyping. Exclusion criteria were: an in-frame DMD mutation and/or preserved dystrophin expression in the muscle biopsy; inability to carry out a reliable PUL test as ascertained by trained evaluators. Patients from the Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG-DNHS) were used as validation cohort; inclusion criteria and cohort characteristics have been previously described [15].

DMD genotype

Information about pathogenetic DMD mutations was collected when available from clinical records or genetic reports. Patients were clustered, according to DMD gene mutations and their amenability molecular treatments, i.e. skipping of exons 8, 44, 45, 51, and 53 (henceforth: “skip 8”, “skip 44”, etc.), duplications, splice site mutations, and nonsense mutations. Rarer deletions were clustered in the “other deletions” subset. Missense mutations were not present in our population.

PUL test

The PUL scale version 1.2 was used to evaluate the performance of upper limbs in the Italian cohort as previously described by Mayhew and colleagues [16]. The test is composed of 22 items, 21 of which assess the functionality of upper limbs, divided in 3 domains: proximal domain (henceforth “Shoulder”), medial domain (henceforth “Elbow”), and distal domain (henceforth “Distal”). The first item (item A) allows to evaluate overall proximal function, and is very similar to the Brooke scale (supplementary table 1 for Brooke and PUL scale comparison). Total PUL score is calculated by the sum of all items, except item A.

Brooke scale

To assess upper limb function in the validation cohort, the Brooke scores was used. On the Brooke scale (range from 1 to 6), a score equal to 1 is considered when the patient is able to start with arms at the sides and can abduct the arms in a full circle until they touch above the head, while 6 means they have no useful hand function [13]. All functional assessments were performed by trained physiotherapists.

Targeted genotyping

Patients’ DNA samples were genotyped, using TaqMan (Thermo Fisher Scientific) assays, at these known DMD modifier loci: SPP1 rs28357094 [7], LTRBP4 rs10880, rs2303729 and rs1131620 [8], CD40 rs1883832 [9], ACTN3 rs1815739 [10]. For tests of genotype/phenotype association, we used the same inheritance models as in published reports. Allele frequencies were tested for Hardy–Weinberg equilibrium.
**Statistical analyses**

Quantitative variables were summarized as mean ± standard deviation (SD) and median (range), unless otherwise specified. Intervals of linear decrease of PUL scores (Total PUL, Shoulder, Elbow, and Distal) measures were defined on the age axis by piecewise regression, using baseline data (i.e. earliest available value) and choosing a 1-break model for total PUL, Elbow and Distal, and linear model without break point for Shoulder after visual inspection of the scatter plot. Generalized Estimating Equations (GEEs) were used to estimate effects of: age, GC treatment (on vs. off at each evaluation), DMD mutation, and SNP genotypes (dominant, recessive, or additive as appropriate). GEEs were applied within the “linear” age range defined by piecewise regression. The validation cohort was tested using GEE models to analyze the effect of SNPs genotype, age, and GC treatment (considered “true” when patients have taken them for at least one year in their life) on the Brooke score. Statistical analyses were performed with R v.4.0.2.

**Results**

**PUL cohort**

The Italian multi-centric cohort was composed of 137 patients. The average age was 11.38 ± 5.22 (minimum age: 4.17, maximum: 28.59). During follow-up, 88 patients (64.2%) were continuously on GCs, 32 (23.4%) were never on GCs, 15 (10.9%) switched on/off (5 patients started, 10 stopped) and 2 (1.5%) had no available GC treatment data. There were significant differences in age between GC treatment subgroups (Kruskal–Wallis test \( p < 0.001 \)). Patients who were continuously on GCs were younger (10.14 ± 4.05, range 4.17–24.75 years) than those continuously off GCs (15.98 ± 6.19, range 4.83–28.59 years), and patients who started GCs during follow-up were the youngest subgroup (6.99 ± 2.81, range 4.31–11.61 years).

**PUL results**

A total of 636 PUL assessments were obtained from the 137 patients, 125 of whom had more than one PUL evaluation available, with a mean of 4.64 evaluations per patient (range 1–15 PULs/patient). Mean ± standard deviation of follow-up duration was 2.82 ± 1.30 years (range 0.98–5.70 years). Mean age at first evaluation was 11.38 ± 5.22 years (range 4.17 sec 228.59 years), while at last evaluation it was 14.16 ± 5.26 years (range 5.69–29.67 years).

Total and domain-specific scores at baseline increased until approximately 6–8 years of age, and then decreased progressively (as expected). We used the piecewise regression model to estimate the ranges of linear decrease of total PUL and sub-domains scores. We found that total PUL total score decreases in a linear fashion starting from age of 7.5, shoulder score from 6.7, elbow from 8.9, and distal from 8.7 years of age. Stratifying patients based on GC treatment, treated patients had higher PUL scores compared to non-treated, although there was a decreasing trend with age in both treated and untreated patients. Regarding total PUL scores, it appears that the rate of decline is similar between treated and untreated groups, but with higher values for treated, likely because of a higher and longer plateau of maximum function. The domain which seems to differentiate most between treated and untreated subgroups is the elbow domain, while shoulder and distal domain appear less differentiated.

**Brooke results**

A total of 2895 evaluations were obtained with Brooke test from 340 patients of CINRG-DNHS cohort. Two hundred and eighty of them had more than one evaluation available, with a mean Brooke score at baseline. The mean follow-up time was 5.6 ± 2.41 years (range 0.23–9.9 years). The mean age at the first evaluation was 11.98 ± 5.8 years (range 2.05–28.01 years), while at the last evaluation, it was 17.59 ± 5.78 years (range 4.5–33.85 years).

**Genotyping results**

Patients from the two cohorts were genotyped for \( SPP1 \) rs28357094, \( CD40 \) rs1883832, \( LTBP4 \) rs2303729, rs1131620 and rs10880, and \( ACTN3 \) rs1815739. In both cohorts, there were patients for whom it was not possible to assess Genotype at all the SNPs, in particular: \( CD40 \) rs1883832 data were missing for 2 patients from the Italian and 63 from the CINRG cohort, \( LTBP4 \) rs1131620 data were missing for 1 patient belonging to the Italian cohort and 82 from the CINRG cohort, \( LTBP4 \) rs10880 genotype was not available for 3 patients from the Italian and 66 from the CINRG cohort, \( LTBP4 \) rs2303729 was missing for 75 CINRG patients, \( SPP1 \) rs28357094 data were missing for 61 patients from the CINRG cohort, and it was not possible to assess the genotype at \( ACTN3 \) rs1815739 for 1 Italian and 75 CINRG patients. All the genotypes did not deviate from the Hardy–Weinberg equilibrium, and the observed MAFs were compatible with those expected from the European population.

**GEE models**

To determine if the genotypes at the modifier loci, together with patient’s age and GCs treatment, influence the PUL
scores (total, shoulder, elbow and distal) in the Italian cohort or Brooke score in CINRG-DNHS, we used the GEE model. Results are summarized in Tables 1 and 2.

These models estimated linear coefficients of yearly decrease for the total score and domain sub-scores, which are similar, but slightly lower than those estimated by simple linear regression using baseline scores only. This result may be expected based on the statistical features of the models.

In the Italian cohort, coefficients relative to GC treatment status at the time of each PUL evaluations corresponded to +11.19 points in the total score ($p<0.001$), +1.15 points in the elbow sub-score ($p=n.s.$), +9.35 points in the elbow sub-score ($p<0.001$), and +2.08 points in the distal sub-score ($p<0.001$). Notably, coefficients relative to GC treatment here presented are not dependent on grouping of individual patients based on treatment status, but refer to GC treatment as a dichotomic variant (on vs. off) at each PUL evaluation included in the model.

The inheritance models used for SNPs were based on those found in the literature (see Methods). In regard to $LTBP4$, here we present results relative to the isolated rs10880 genotype (the most strongly associated with phenotypes in published literature), but alternative models for the IAAM homozygous haplotype were also explored with similar findings (data not presented). In a multivariate GEE model, it was possible to assess a significant association of $CD40$ rs1883832 (dominant) with the Brooke score. Moreover, it was possible to test the isolated association of $SPP1$ rs28357094 (additive model) and $CD40$ rs1883832 (dominant model) with the Brooke score.

**Mutation analyses**

$DMD$ gene mutations were fully characterized for 96 patients from the Italian cohort and were divided as follows: 64 (64/96, 66.7%) were deletions of one or more exons; 9 (9/96, 9.4%) duplications of one or more exons, and the remaining 23 (23/96, 23.9%) were small intraexonic or intronic mutations.

The mutations were divided in groups based on their eligibility for exon skipping or other molecular treatments (see Methods). The remaining mutations were divided into duplications, nonsense mutations, splice site mutations, and other deletions (when not classifiable to other groups).

Significant correlation was found for the skip 45, skip 8 and skip 53 and skip 51 groups. The skip 45 group was positively correlated (beneficial effect) with total PUL scores ($p=0.042$) and shoulder sub-scores ($p=0.002$), and with GC treatment on Brooke score in the CINRG-DNHS cohort. The coefficients relative to GC treatment status at the time of each evaluations corresponded to +0.95 points ($p<0.001$), for the Brooke score. Moreover, it was possible to test the isolated association of $CD40$ rs1883832 (dominant model) and $SPP1$ rs28357094 (dominant) with the Brooke score.

**Table 1** Estimates of effects of several variables on longitudinal PUL measures, based on GEE models, in patients with age ≥7.51 years in the Italian cohort

| Parameter          | PUL            | Shoulder       | Elbow          | Distal         |
|--------------------|----------------|----------------|----------------|----------------|
|                    | Estimate p value | Estimate p value | Estimate p value | Estimate p value |
| Intercept          | 78.49 <0.001    | 20.61 <0.001   | 33.60 <0.001   | 23.51 <0.001   |
| Age                | -1.97 <0.001   | -0.91 <0.001   | -0.82 <0.001   | -0.16 <0.001   |
| GC                 | 11.19 <0.001   | 1.15 n.s       | 9.35 <0.001    | 2.08 <0.001    |
| $SPP1$ rs28357094 dom | -1.49 n.s     | -0.49 n.s     | -1.71 n.s      | -0.12 n.s      |
| $CD40$ rs1883832 add | -3.07 0.076    | -1.55 0.023   | -1.11 n.s      | -0.65 0.018    |
| $ACTN3$ rs1815739 add | -2.20 n.s    | -0.63 n.s     | -2.09 0.030    | -0.61 0.025    |
| $LTBP4$ rs10880 rec | -0.12 n.s     | -1.13 n.s     | 0.83 n.s       | -0.06 n.s      |

$PUL$ performance of upper limbs, $GC$ glucocorticoid treatment. The models adopted for SNPs are dominant (dom), recessive (rec) or additive (add)

**Table 2** Estimates and $p$ values for two-tailed tests for SNPs researched on a subset of the CINRG-DNHS cohort

| Parameter      | Brooke Estimate p value |
|----------------|-------------------------|
| $SPP1$ rs28357094 dom | 0.28 0.034 |
| $CD40$ rs1883832 add | 0.29 0.018 |
| $ACTN3$ rs1815739 add | 0.21 0.2 |
| $LTBP4$ rs10880 rec | -0.30 1 |

$CD40$, $SPP1$, $ACTN3$, and $LTBP4$ gene mutations were fully characterized for 96 patients from the Italian cohort and were divided as follows: 

- 64 (64/96, 66.7%) were deletions of one or more exons; 
- 9 (9/96, 9.4%) duplications of one or more exons, and 
- the remaining 23 (23/96, 23.9%) were small intraexonic or intronic mutations.

The mutations were divided in groups based on their eligibility for exon skipping or other molecular treatments (see Methods). The remaining mutations were divided into duplications, nonsense mutations, splice site mutations, and other deletions (when not classifiable to other groups).

Significant correlation was found for the skip 45, skip 8 and skip 53 and skip 51 groups. The skip 45 group was positively correlated (beneficial effect) with total PUL scores ($p=0.042$) and shoulder sub-scores ($p=0.002$), and with GC treatment on Brooke score in the CINRG-DNHS cohort. The coefficients relative to GC treatment status at the time of each evaluations corresponded to +0.95 points ($p<0.001$), for the Brooke score. Moreover, it was possible to test the isolated association of $CD40$ rs1883832 (dominant model) and $SPP1$ rs28357094 (dominant) with the Brooke score.
distal subscores ($p=0.017$), but not with elbow subscores. The skip 53 and skip 51 groups were negatively correlated (detrimental effect) with PUL scores, but only at the elbow level ($p<0.001$ and 0.012, respectively) level. The skip 8 group was found to be positively correlated with the PUL scores with regard to total PUL scores ($p=0.015$), shoulder level ($p<0.001$), elbow level (0.037), and distal level ($p=0.002$). It is necessary to note that the skip 8 and skip 45 groups were small (skip 8 = 3 patients, skip 45 = 5 patients), with relatively young patients and little variability in age. Concerning the CINRG cohort, $DMD$ gene mutations were

---

**Fig. 1** Scatter plots of PUL values grouped by $CD40$ rs1883832 genotype. Individual data points (which may include multiple data points from individual patients) are color-coded based on genotype, and a regression line for each genotype group is plotted. The vertical dashed lines, annotated on top with the corresponding value on the $x$ (i.e. age) axis, indicate the age at which the piecewise regression models predicts the beginning of a linear decline of the measure. Panel A shows total PUL scores, while panels B, C, and D show subscores for the shoulder, elbow, and wrist domains, respectively.
fully characterized for 287 patients and were divided as follows: 208 (208/287, 72.5%) were deletions of one or more exons; 14 (14/287, 4.8%) duplication of one or more exons; and the remaining 65 (65/287, 22.6%) were small intraexonic or intronic mutations. None of these mutation groups was significantly associated with Brooke scores Table 3.

Fig. 2 Scatter plots of PUL values grouped by \textit{ACTN3} rs1815739 genotype. The T genotype corresponds to a null \textit{ACTN3} allele (nonsense SNP). Individual data points (which may include multiple data points from individual patients) are colored based on genotype (see legend), and a regression line for each genotype group is plotted. The vertical dashed lines, annotated on top with the corresponding value on the x (i.e. age) axis, indicate the age at which the piecewise regression models predicts the beginning of a linear decline of the measure. Panel A shows total PUL scores, while panels B, C, and D show subscores for the shoulder, elbow, and wrist domains, respectively.
Discussion

The primary goal of this work was to describe the clinical course of the disease in our population based on the PUL score. We performed a piecewise regression on the baseline data finding a breakpoint at 7.512 years. Considering the clinical history of the disease, this finding was not surprising, as patients with DMD early on improve their motor abilities. In fact, also for ambulation-related phenotypes (6MWT, NSAA) it is usually possible to observe a plateau phase around 7 years of age [17], and only then, with the progression of the disease, motor function worsens. It is relevant that the age of the plateau of upper limb function was similar to that of ambulatory function, as this region is the last to lose its motor function. Importantly, one has to consider the limits of ordinal data such as clinical scale scores, when linear methods are applied. As a general rule, linear methods can be reliably applied to ordinal data if the scale has a sufficiently large number of levels (as is the case of PUL with 74 levels) and sufficient reliability. A positive correlation of GC treatment on PUL performance was confirmed, but there was an unexpected finding. Considering both the SNPs and the mutational group, the association with GC that was extremely significant when considering total PUL scores ($p < 0.001$, $p = 0.01$), became non-significant when considering only the partial scores of the shoulder. This anomaly could be caused by the fact that the shoulder level starts to be affected early on, when children are young and are not yet under GC treatment. The significance is then again high when considering the other two levels of PUL. This can be interpreted as a limit of an observational, retrospective study, in which patients are not randomized to treatment.

Table 3: Estimates and p-values for the groups of mutations considered in the Italian and CINRG cohorts

| Parameter | PUL Estimate | PUL p-value | PUL Shoulder estimate | PUL Shoulder p-value | PUL Elbow estimate | PUL Elbow p-value | PUL Distal estimate | PUL Distal p-value | Brooke estimate | Brooke p-value |
|-----------|--------------|-------------|-----------------------|---------------------|-------------------|-------------------|-------------------|-------------------|----------------|--------------|
| Intercept | 74.244       | <0.001      | 18.413                | <0.001              | 29.790            | <0.001            | 21.799            | <0.001            | -1.513         | <0.001        |
| Age       | -1.755       | <0.001      | -0.850                | <0.001              | -0.632            | <0.001            | -0.112            | <0.001            | 0.207          | <0.001        |
| GC        | 9.732        | 0.007       | 0.822                 | n.s.                | 9.259             | <0.001            | 2.281             | 0.004             | 1.027          | <0.001        |
| Skip 8    | 7.026        | 0.015       | 5.110                 | <0.001              | 2.049             | 0.037             | 1.139             | 0.002             | -1.449         | <0.001        |
| Skip 44   | 3.431        | n.s.        | 1.367                 | n.s.                | 0.467             | n.s.              | 0.424             | n.s.              | -0.317         | n.s.          |
| Skip 45   | 5.483        | 0.042       | 2.766                 | 0.002               | 2.513             | n.s.              | 1.569             | 0.017             | -0.012         | n.s.          |
| Skip 51   | -6.011       | n.s.        | -1.066                | n.s.                | -4.224            | 0.012             | -1.090            | n.s.              | 0.253          | n.s.          |
| Skip 53   | -8.336       | n.s.        | -1.368                | n.s.                | -9.435            | <0.001            | -1.847            | n.s.              | 0.152          | n.s.          |
| Splice    | 2.513        | n.s.        | 1.954                 | n.s.                | -0.316            | n.s.              | 0.766             | n.s.              | NA             | NA            |
| Duplications | -0.640      | n.s.        | 0.177                 | n.s.                | -1.350            | n.s.              | 0.321             | n.s.              | 0.097          | n.s.          |
| Nonsense  | -1.876       | n.s.        | -1.025                | n.s.                | -1.132            | n.s.              | 0.638             | n.s.              | 0.243          | n.s.          |

PUL estimates of covariates associated with higher PUL scores are colored in green; PUL estimates of covariates associated with lower PUL scores are colored in red. Significant p-values are highlighted in bold. PUL: Performance of Upper Limbs; NA: not available; n.s.: not significant.
Among the genetic modifiers we considered, only *SPP1* had been previously validated using grip strength (i.e. upper limb muscle strength) [7], and thus it would have been reasonable to expect similar results using the PUL and Brooke scale. However, we found a significant association between the G allele at the promoter of *SPP1* and upper limb strength only in the CINRG cohort. Possible explanations of the lack of significance in the Italian population may include a relatively small effect of the allele, and the relatively low proportion of patients on continuous GC treatment (64%) in this cohort, since it has been proposed that *SPP1* genotype acts as a modulator of GC response [18].

The second genetic modifier analyzed was rs1815739 in *ACTN3*. This SNP predicts a null polymorphism, thus homozygous individuals show absence of α-actinin-3 in muscle. The loss of α-actinin-3 has a complex effect in muscle, decreasing strength but supposedly ameliorating the clinical course in the long term, probably because of a shift from fast-type to slow-type muscle fibers, the latter being relatively spared in DMD. Hogarth et al. showed an effect of rs1815739 on LoA, 6MWT, and strength of upper and lower limbs, however the effect on LoA did not reach statistical significance [10]. In our study, while there were no significant associations with PUL in general, nor with Brooke performances, we did find significant associations with elbow and distal PUL scores, in the same direction (i.e. detrimental) as earlier LoA and reduced grip strength previously reported [10]. It is reasonable that reduced strength associated with α-actinin-3 may reduce ability in PUL items which require maximal efforts (e.g. lifting heavy weights or tearing folded paper). Furthermore, muscles in the arms, forearms, and hands, which are known to contain a high ratio of type II glycolytic fibers where this isoform of actinin is mostly expressed, may be more affected than proximal, larger muscles, which have a higher proportion of type I fibers. Our findings may represent an indirect validation of the modifier effect of *ACTN3*, using phenotypes that are not identical but correlated to the same underlying variable, i.e. muscle strength.

The third genetic modifier considered in this study is rs1883832 in *CD40*, that showed the strongest association with PUL and Brooke scores. The direction of the effect was negative for the minor T allele, in concordance with described effects on LoA. The estimated linear coefficients of yearly decrease showed a higher impact at the shoulder level than at the distal level. The lesser effect at distal level seems plausible considering the progression of DMD, in which the distal level is the last and least affected. The effect of rs1883832 has been confirmed also in the validation cohort (\(p = 0.018\) for the Brooke scale). The putative mechanism of action of *CD40* minor allele “T” could be in decreasing muscle regenerative ability and increasing fibrosis. In fact, the transition from innate to adaptive immunity, in which CD40 is implicated, is relevant in muscular dystrophy, especially with regards to the balance between macrophages with pro-fibrotic (M1) vs pro-regenerative (M2) phenotype [9, 19].

The last examined genetic modifier was *LTBP4*, for which we failed to find significant association between PUL scores and all the SNPs in *LTBP4* genotypes. The same result was obtained with the validation cohort. This was somewhat surprising, given that *LTBP4* appears to be one of the modifiers with the largest effect size, and most consistently validated across international cohorts [8, 18, 20].

As mentioned previously, the phenotypic variability that can be observed in DMD patients can be partially explained by different types of DMD mutations. For these reasons, we chose to select a few specific groups of mutations, as analyzing each single mutation would have led to an excessive fragmentation of the cohort, barring statistically significant conclusions. The effect of different mutations on age at LoA has been reported by several recent studies. The greater effect was seen in patients amenable to exon skipping of exons 44 [21, 22], 8 [5, 18] and 51 [23], where those eligible to skipping of exon 44 and 8 had a milder phenotype with a delay in age at LoA and patients amenable to skipping of exon 51 had a poorer outcome. Patients amenable to exon skipping of exon 53 had also been found to be associated with a different clinical course than other mutations. Servais et al. reported a greater severity linked to this phenotype, with lower left ventricular ejection, more severe contractures, reduced strength in upper limbs, and earlier age at LoA relatively to other theoretical skip groups considered [24].

In our study, a significant association between “skip44” group and PUL scores was not confirmed, despite the ample evidence in the literature of an effect on ambulatory phenotypes. We have found instead a significant association between the “skip45” group and the PUL scores, with a favorable effect on the function of upper limb considering the total PUL scores (\(p = 0.042\)), the shoulder level (\(p = 0.002\)) and the distal level (\(p = 0.017\)). The significance was not found for elbow level. There is no obvious rational explanation for this difference. Considering the small number of patients in this group and their relatively young age, these results may be a result of bias, and therefore should be validated in a larger cohort before this association can be established. Statistically significant reductions of PUL scores were found in the “skip53” group, already reported to have poorer prognosis [24]. However, in our population, statistical significance was found only at the elbow level (\(p < 0.001\)). Comparable results were found for “skip51” subgroup, with statistically significant reductions of PUL subscores at elbow level (\(p = 0.012\)). A poorer prognosis in “skip51” subgroup has been already reported by Wang et al. [5] As both the patients in “skip51” and “skip53” subgroups...
are deficient of the Dp140 dystrophin isoform, which is largely expressed in the brain, and have higher incidence of cognitive issues [25, 26], it may be that executive function issues impair PUL scores to some extent. Although small, the “skip8” group was the one that we found to have the most significant association with PUL total score ($p = 0.02$). As reported in the literature [22, 27–29] for overall and ambulatory phenotypes [22, 27–29], this group had a milder course, with slower decrease in PUL score. This effect was present not only on total PUL score, but also at the shoulder level ($p < 0.001$) and elbow level ($p = 0.04$). This group in our population was comprised of only 3 patients, and their age distribution was skewed toward the younger age, and this could theoretically bias our results. However, the effect seems expected based on literature data, and is probably genuine. In fact, our group was comprised of three patients, two still ambulating and one with age at LoA of 16.1 years, which is higher than the average age of LoA.

In conclusion, we describe the natural history of upper limb dysfunction in DMD by identifying ages of maximum function before the start of deterioration at the global, shoulder, elbow, and distal levels. We confirmed that shoulder function is lost earlier, and quantified yearly decline rates of PUL scores. We identified significant effects of CD40 genotype on shoulder and distal function (the rs1883832 T allele being detrimental), and of ACTN3 on elbow and distal function considering the Italian cohort, and confirmed the detrimental effect of the G allele in SPP1 rs28357094 allele in the validation cohort. Deletions amenable to exon 44 skipping did not show clearly preserved upper limb function, which was clear with deletions amenable to exon 8 skipping. Deletions eligible for exon 53 and 51 skipping, on the other hand, showed worse impairment of elbow function than average DMD. All these findings will be useful in designing and interpreting clinical trials in DMD, especially when targeting populations across the ambulatory and non-ambulatory range; moreover, identified genetic modifiers may be considered as potential therapeutic targets.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00415-022-11133-8.

Acknowledgements We wish to thank all participating patients. We acknowledge funding from Fondazione Telethon (GUP1002) for collection of clinical data in the Italian cohort. EP also acknowledges funding from the Cariparo Foundation (Progetto di Eccellenza “Gen-Mod” 2017), and from Telethon Genetic BioBank (GTB12001D) and the Eurobiobank Network. The CINRG-DNHS was funded by the U.S. Department of Education/NIDRR (#H133B031118, #H133B090001); U.S. Department of Defense (#W81XWH-12-1-0417); National Institutes of Health/NIAMS (#R01AR061875); Parent Project Muscular Dystrophy, LB, EP, LP, TM, AD, EB, RM, CB, GPC, FM, SP, SM are part of the European Reference Network for neuromuscular diseases.

Declarations

Conflicts of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical approval Consent was obtained from adult patients or parents/guardians of minors included in the study cohorts. All clinical investigation were conducted according to the principles expressed in the Declaration of Helsinki, and approved by the Institutional Ethic Committee at each participating Center.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Darras BT, Urion D K, Ghosh PS (2018) Dystrophinopathies summary: genetic counseling GeneReview Scope 1–35
2. Humbertclaude V et al (2012) Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur J Paediatr Neurol 16:149–160
3. Pane M et al (2014) 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS One 9:e83400
4. Barp A et al (2015) Genetic modifiers of duchenne muscular dystrophy and dilated cardiomyopathy. PLoS One 10:1–14
5. Wang RT et al (2018) DMD genotype correlations from the Duchenne Registry: endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. Hum Mutat 39:1193–1202
6. Bello & Pegoraro (2019) The “usual suspects”: genes for inflammation, fibrosis, regeneration, and muscle strength modify muscular dystrophy. J Clin Med 8:649
7. Pegoraro E et al (2011) SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 76:219–226
8. Flanigan KM et al (2013) LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy. Ann Neurol 73:481–488
9. Bello L et al (2016) Association study of exon variants in the NF-xB and TGFβ pathways identifies CD40 as a modifier of Duchenne Muscle dystrophy. Am J Hum Genet 99:1163–1171
10. Hogarth MW et al (2017) Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy. Nat Publ Gr 8:1–13
11. Weiss RB, Vieland VJ, Dunn DM, Kaminoh Y, Flanigan KM (2018) Long-range genomic regulators of THBS1 and LTBP4 modify disease severity in duchenne muscular dystrophy. Ann Neurol 84:234–245
12. Pascual-Morena C et al (2021) Genetic modifiers and phenotype of Duchenne muscular dystrophy. A systematic review and meta-analysis. Pharmaceuticals 14:798
13. Brooke MH et al (1981) Clinical trial in duchenne dystrophy. I. The design of the protocol. Muscle Nerve 4:186–197
14. Pane M et al (2018) Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLoS One 13:4–11
15. McDonald CM et al (2013) The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used. Muscle Nerve 48:32–54
16. Mayhew A et al (2013) Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55:1038–1045
17. Marzzone ES et al (2009) Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 19:458–461
18. Bello L et al (2015) Genetic modifiers of ambulation in the cooperative international neuromuscular research group Duchenne natural history study. Ann Neurol 77:684–696
19. Rosenberg A et al (2015) Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med 7:299rv4
20. van den Bergen JCJC et al (2015) Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J Neurol Neurosurg Psychiatry 86:1060
21. van den Bergen JC, Jinjaar HB, Niks EH, Aartsma-Rus A, Verschuuren JJGM (2014) Prolonged ambulation in duchenne patients with a mutation amenable to exon 44 skipping. J Neuromuscul Dis 1:91–94
22. Bello L et al (2016) DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study. Neurology 87:401–409
23. Wang M, Birnkrant DJ, Super DM, Jacobs IB, Bahler RC (2018) Progressive left ventricular dysfunction and long-term outcomes in patients with Duchenne muscular dystrophy receiving cardiopulmonary therapies. Open Hear 5:e000783–e000783
24. Servais L et al (2015) Non-ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype. J Neuromuscul Dis 2:269–279
25. Felisari G et al (2000) Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy. Neurology 55:559–564
26. Doorenweerd N et al (2017) Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. Sci Rep 71(7):1–12
27. Winnard AV, Mendell JR, Prior TW, Florence J, Burghes AH (1995) Frameshift deletions of exons 3–7 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production. Am J Hum Genet 56:158
28. Gualandi F et al (2006) Intronic breakpoint definition and transcription analysis in DMD/BMD patients with deletion/duplication at the 5′ mutation hot spot of the dystrophin gene. Gene 370:26–33
29. Muntoni F et al (1994) Deletions in the 5′ region of dystrophin and resulting phenotypes. J Med Genet 31:843

Authors and Affiliations

Daniele Sabbatini1 · Aurora Fusto1 · Sara Vianello1 · Matteo Villa1 · Joanna Janik1 · Grazia D’Angelo2 · Eleonora Diella2 · Francesca Magri3 · Giacomo P. Comi3 · Chiara Panicucci4 · Claudio Bruno4 · Adele D’Amico5 · Enrico Bertini5 · Guja Astrea6 · Roberta Battini6 · Luisa Politano7 · Riccardo Masson8 · Giovanni Baranello8,9 · Stefano C. Previtali10 · Sonia Messina11 · Gianluca Vita11 · Angela Berardinelli12 · Tiziana Mongini13 · Antonella Pini14 · Marika Pane15,16 · Eugenio Mercuri15,16 · Eric P. Hoffman17,18 · Lauren Morgenroth18 · Heather Gordish-Dressman18 · Tina Duong19,18 · Craig M. McDonald20 · Luca Bello1 · Elena Pegoraro1

1 Department of Neurosciences DNS, University of Padova, via Giustiniani, 5, 35128 Padua, Italy
2 Scientific Institute IRCCS E. Medea, Neuromuscular Unit, Lecco, Bosisio Parini, Italy
3 IRCCS Foundation, Ca’ Granda Ospedale Maggiore Policlinico; Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy
4 Center of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health–DINOGMI, University of Genoa, Genoa, Italy Genoa, Italy
5 Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy
6 Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy
7 Cardiology and Medical Genetics, Department of Experimental Medicine, “Vanvitelli” University of Campania, Naples, Italy
8 Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
9 The Dubowitz Neuromuscular Centre, NIHR BRC University College London Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK
10 Neuromuscular Repair Unit, Inspe and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
11 Department of Neurosciences and Nemo Sud Clinical Center, University of Messina, Messina, Italy
12 C. Mondino Foundation, Pavia, Italy
13 Neuromuscular Center, AOU Città Della Salute E Della Scienza, University of Torino, Turin, Italy
14 Pediatric Neuromuscular Unit, IRCCS Istituto Delle Scienze Neurologiche Di Bologna, Bologna, Italy
15 Pediatric Neurology, Department of Woman and Child Health and Public Health, Università Cattolica del Sacro Cuore, Child Health Area, Rome, Italy
16 Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
17 Binghamton University · SUNY, Binghamton, NY, USA

Springer
18 Center for Genetic Medicine, Children’s Research Institute, Children’s National Health System, Washington, DC, USA

19 Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA

20 University of California Davis Medical Center, Sacramento, CA, USA